Category: Medtech M&A
-
Clinical Evidence Requirements for Medtech: What You Need and When
Medical device companies face a complex landscape when determining their clinical evidence requirements. The path forward depends on multiple factors including device classification, predicate devices, and regulatory pathway. Understanding these requirements early in development can mean the difference between a smooth regulatory submission and costly delays. This oversight can derail product launches and strain resources… Read more
-
What Buyers Look For in a Regulatory Due Diligence Review
When private equity firms and strategic acquirers evaluate life sciences companies, the regulatory landscape often determines whether a promising deal moves forward or stalls indefinitely. Thorough regulatory due diligence can either validate an acquisition thesis or reveal hidden risks that fundamentally alter deal terms. For M&A buyers in the medtech, pharma, and nutraceutical sectors, understanding… Read more
-
The Difference Between a Compliance Audit and a Regulatory Readiness Check
The Difference Between a Compliance Audit and a Regulatory Readiness Check Understanding the distinction between a compliance audit and a regulatory readiness check is crucial for companies navigating the complex world of FDA regulations. While both assessments evaluate your organization’s adherence to regulatory requirements, they serve different purposes, occur at different stages of your business… Read more
-
What Health & MedTech Founders Should Fix Before Starting M&A Conversations
What Founders Should Fix Before Starting M&A Conversations The M&A landscape for life science has never been more competitive. While strategic acquirers and private equity firms actively seek innovative medtech, pharma, and nutraceutical companies, they’re increasingly selective about the deals they make. In our experience working with companies through acquisition processes, the consistently same critical… Read more
-
Why Regulatory Readiness is the Most Overlooked Factor in M&A Valuations
When private equity firms and strategic acquirers evaluate life sciences companies, they typically focus on market size, intellectual property, and potential for financial performance. Yet one critical factor consistently gets relegated to the back burner: regulatory readiness. Our 25+ years of experience with medtech, pharma, and nutraceutical companies has caused us to witness how regulatory… Read more